Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 211 to 220 of 596 total matches.

Xywav - A Mixed-Salt Oxybate Oral Solution for Idiopathic Hypersomnia

   
The Medical Letter on Drugs and Therapeutics • Dec 27, 2021  (Issue 1640)
for treatment of idiopathic hypersomnia in adults. It is the first drug to be approved ...
Xywav (Jazz), an oral solution that contains calcium, magnesium, potassium, and sodium oxybates, has been approved by the FDA for treatment of idiopathic hypersomnia in adults. It is the first drug to be approved in the US for this indication. Xywav was approved in 2020 for treatment of excessive daytime sleepiness or cataplexy in patients ≥7 years old with narcolepsy. It contains about 92% less sodium than sodium oxybate oral solution (Xyrem), which has been available in the US for years for use in patients ≥7 years old with narcolepsy.
Med Lett Drugs Ther. 2021 Dec 27;63(1640):207-8 |  Show IntroductionHide Introduction

In Brief: OTC Ivermectin for Head Lice

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023  (Issue 1679)
option that has been effective for treatment of head lice resistant to topical drugs.4 MECHANISM ...
Topical ivermectin lotion 0.5% (Sklice, and generics), which has been available by prescription since 2012, is now FDA-approved for sale over the counter (OTC) for treatment of head lice in patients ≥6 months old. Ivermectin is also available by prescription as a 1% cream (Soolantra) approved for topical treatment of inflammatory lesions of rosacea and in oral tablets (Stromectol, and generics) for treatment of various parasitic infections.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):103-4   doi:10.58347/tml.2023.1679e |  Show IntroductionHide Introduction

Epcoritamab (Epkinly) for Diffuse Large B-Cell Lymphoma (DLBCL) (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
or meaning; such suffixes are added to biologic drugs to distinguish reference products ...
Epcoritamab-bysp (Epkinly – Genmab), a bispecific CD20-directed CD3 T-cell engager, has received accelerated approval from the FDA for subcutaneous treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after ≥2 lines of systemic therapy. Epcoritamab is the second T-cell-engaging bispecific antibody to become available in the US for treatment of non-Hodgkin's lymphoma; mosunetuzumab-axgb (Lunsumio) was recently approved for relapsed or refractory...
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e103-4   doi:10.58347/tml.2023.1678d |  Show IntroductionHide Introduction

Cabotegravir/Rilpivirine (Cabenuva) for HIV-1 Infection

   
The Medical Letter on Drugs and Therapeutics • May 31, 2021  (Issue 1625)
to either drug. Oral cabotegravir (Vocabria) was also approved by the FDA for use in combination with oral ...
The FDA has approved Cabenuva (ViiV Healthcare), an extended-release formulation of the new integrase strand transfer inhibitor (INSTI) cabotegravir copackaged with an extended-release formulation of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine, as a once-monthly complete regimen for intramuscular (IM) treatment of adults with HIV-1 infection who are virologically suppressed (HIV-1 RNA...
Med Lett Drugs Ther. 2021 May 31;63(1625):81-3 |  Show IntroductionHide Introduction

Tenapanor (Ibsrela) for Irritable Bowel Syndrome with Constipation

   
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022  (Issue 1652)
) can be tried (see Table 3).3 All of these drugs have been modestly effective in reducing abdominal ...
The FDA has approved tenapanor (Ibsrela - Ardelyx), a sodium/hydrogen exchanger 3 (NHE3) inhibitor, for twice-daily oral treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Tenapanor is the first NHE3 inhibitor to become available in the US.
Med Lett Drugs Ther. 2022 Jun 13;64(1652):91-4 |  Show IntroductionHide Introduction

An EUA for Baricitinib (Olumiant) for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020  (Issue 1614)
in combination with the IV antiviral drug remdesivir (Veklury).1 Baricitinib has been available for treatment ...
The oral Janus kinase (JAK) inhibitor baricitinib (Olumiant – Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of confirmed or suspected COVID-19 in hospitalized patients ≥2 years old who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO); the EUA requires that baricitinib be used in combination with the IV antiviral drug remdesivir (Veklury). Baricitinib has been available for treatment of rheumatoid arthritis since 2018. Remdesivir was recently approved by the FDA for treatment of COVID-19 in...
Med Lett Drugs Ther. 2020 Dec 28;62(1614):202-3 |  Show IntroductionHide Introduction

Delayed-Release Budesonide (Tarpeyo) for Primary Immunoglobulin A Nephropathy

   
The Medical Letter on Drugs and Therapeutics • May 16, 2022  (Issue 1650)
; also called Berger's disease) who are at risk of rapid disease progression. It is the first drug ...
The FDA has approved Tarpeyo (Calliditas), a delayed-release capsule formulation of the corticosteroid budesonide, to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN; also called Berger's disease) who are at risk of rapid disease progression. It is the fi rst drug to be approved in the US for this indication. Oral formulations of budesonide have been available for years for treatment of inflammatory bowel disease.
Med Lett Drugs Ther. 2022 May 16;64(1650):76-7 |  Show IntroductionHide Introduction

Nalmefene Returns for Reversal of Opioid Overdose

   
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022  (Issue 1658)
glucuronidation Elimination Primarily in urine Half-life 10.8 hours Table 2. Some Drugs for Reversal of Opioid ...
The FDA has approved a generic injectable formulation of the opioid antagonist nalmefene (Purdue) for the management of known or suspected opioid overdose. Revex, the reference product, was withdrawn from the market in 2008 for commercial reasons.
Med Lett Drugs Ther. 2022 Sep 5;64(1658):141-2 |  Show IntroductionHide Introduction

Opill — An OTC Oral Contraceptive

   
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023  (Issue 1685)
was based on data demonstrating that the drug is safe and effective for use as directed in the labeling ...
The FDA has approved Opill (Perrigo), a progestin-only oral contraceptive that contains norgestrel, for sale over the counter (OTC). Opill is the first oral contraceptive to be approved in the US for sale without a prescription. Approval of OTC Opill is intended to increase access to effective contraception and reduce the rate of unintended pregnancies.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):151-2   doi:10.58347/tml.2023.1685c |  Show IntroductionHide Introduction

Lotilaner (Xdemvy) for Demodex Blepharitis

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024  (Issue 1705)
of Demodex blepharitis. Lotilaner is the first drug to be approved in the US for this indication. Table 1 ...
The FDA has approved a 0.25% ophthalmic solution of the ectoparasiticide lotilaner (Xdemvy – Tarsus) for treatment of Demodex blepharitis. Lotilaner is the first drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):99-100   doi:10.58347/tml.2024.1705b |  Show IntroductionHide Introduction